

**Memorial Sloan-Kettering Cancer Center and
Weill Medical College of Cornell University
Required Format for *Curriculum vitae* and Bibliography**

Date of preparation: March 6, 2016

A. GENERAL INFORMATION

1. Name: **Evis Sala, MD, PhD, FRCR**
2. Office address: Memorial Sloan Kettering Cancer Center
1275 York Avenue
Room C-276D
New York, NY 10065
Office telephone: 212-639-2179
Office fax: 212-794-4010
3. Home address 345 E. 68th Street
Apt 6E
New York, NY 10065
Home Telephone: 917-261-4679
4. Cell phone: 646-531-5135
5. Beeper: 8229
6. Email: salae@mskcc.org
7. Citizenship: British
If not USA, do you have Permanent resident
(a) An immigrant visa?
(b) A non-immigrant visa?
8. Optional information:
 - a. Date of birth: N/A
 - b. Place of birth: N/A
 - c. Marital status: N/A
 - d. Spouse's name: N/A
 - e. Children's name and ages: N/A
 - f. Race/Ethnicity: N/A
 - g. Languages spoken/written: English, Italian, French, Albanian
 - h. Gender: Female

B. EDUCATIONAL BACKGROUND

Degree	Institution name and location	Dates attended	Year Awarded
MD	University of Tirana Medical School Tirana, Albania	09/86-07/91	1991
MPhil Epidemiology	University of Cambridge Cambridge, United Kingdom	10/96-08/97	1998
PhD Epidemiology	University of Cambridge Cambridge, United Kingdom	09/97-02/00	2000

C. PROFESSIONAL POSITIONS AND EMPLOYMENT

1. Post-doctoral training

Title	Institution name and location	Dates held
Internship	Oncological Institute Tirana, Albania	07/91-06/92
Staff Physician	Oncological Institute Tirana, Albania	06/92-12/92
Residency Surgery	Oncological Service, University Hospital Centre Tirana, Albania	01/93-09/96
Residency Radiology	Department of Radiology Addenbrookes Hospital Cambridge, United Kingdom	03/00-09/04, 03/05-08/05
Research Fellow Radiology	Memorial Sloan Kettering Cancer Center New York, NY	10/04-03/05

2. Academic positions

Title	Institution name and location	Dates
University Lecturer	University of Cambridge Cambridge, United Kingdom	09/05-06/12
Specialty Teaching Director (Radiology)	School of Clinical Medicine University of Cambridge, Cambridge, United Kingdom	09/08-06/12
Member, MH	Memorial Sloan Kettering Cancer Center New York, NY	07/12-present
Professor of Radiology	Weil Cornell Medical College New York, NY	06/15-present

3. Hospital positions

Title	Institution name and location	Dates held
Consultant Radiologist	Addenbrookes Hospital Cambridge, United Kingdom	09/05-06/12
Lead for Gynaecology Imaging	Addenbrookes Hospital Cambridge, United Kingdom	09/05-06/12

Attending Radiologist	Memorial Hospital for Cancer & Allied Diseases New York, NY	07/12-present
Chief, Body Imaging Service	Memorial Hospital for Cancer & Allied Diseases New York, NY	08/13-present

4. Other Employment

Title	Institution (name and location)	Dates held
N/A		

D. LICENSURE, BOARD CERTIFICATION, MALPRACTICE

1. Licensure

- | | | | |
|----------|--------|---------------|--------------------|
| a. State | Number | Date of issue | Date of Expiration |
| NY | 265060 | 04/30/2012 | 06/30/2015 |
- b. If no license:
- (1) Do you have a temporary certificate?
- (2) Have you passed the examination for foreign medical school graduates?
- c. DEA number: N/A
- d. NPI number: 1962760629

2. Board Certification

Full Name of Board	Certificate #	Date
The Specialist Training Authority of the Medical Royal Colleges, UK	203135	04/20/05

3. Malpractice insurance

Do you have Malpractice Insurance? Yes

Name of Provider: MSK Insurance US, Inc.

Premiums paid by: (*choose one*)

a. self b. group (name) **c. institution (Memorial Sloan Kettering Cancer Center)**

E. PROFESSIONAL MEMBERSHIPS

Member/officer	Name of Organization	Dates held
Member	The Royal College of Radiologists	2000- present
Member	British Institute of Radiology	2003- present
Member	International Society of Magnetic Resonance in Medicine	2003- present
Member	Radiology Society of North America	2004- present

Member	European Society of Radiology	2005- present
Member	International Cancer Imaging Society	2006- present
Member	European Society of Urogenital Radiology	2007- present

F. HONORS AND AWARDS

Name of Award	Date awarded
WHO Fellowship in Cancer Epidemiology	01/92
WHO Fellowship in Cancer Research	09/96
Honorary Cambridge Commonwealth Trust Scholarship	09/97
Overseas Research Students Awards Scheme, UK	09/97
Phillips Travel Bursary, Royal College of Radiologists, UK	09/04
Parke-Davis Fellowship in Biomedical Sciences, Cambridge, UK	09/04
European School of Radiology Tutor Certificate of Appreciation	03/07
European School of Radiology Tutor Certificate of Appreciation	03/08
European School of Radiology Tutor Certificate of Appreciation	03/10
European Congress of Radiology Certificate of Appreciation (Panelist of the Imaging Interpretation Quiz)	03/11
Honorary Member of Spanish Abdominal Imaging Society (SEDIA)	10/11
Journal of Magnetic Resonance Imaging Distinguished Reviewer	2011-2013
RSNA Honored Educator Award	2013
Fellow, International Cancer Imaging Society	2013
European School of Radiology Tutor Certificate of Appreciation	04/14
Fellow, International Society for Magnetic Resonance in Medicine	05/15

G. INSTITUTIONAL/HOSPITAL AFFILIATION

1. Primary Hospital Affiliation: Memorial Hospital for Cancer and Allied Diseases
2. Other Hospital Affiliations: N/A
3. Other Institutional Affiliations: N/A

H. EMPLOYMENT STATUS

1. Name of Current Employer(s): **Memorial Sloan Kettering Cancer Center**
2. Employment Status: Full-time salaried
 - a. Full-time salaried by Cornell
 - b. **Full-time salaried at Cornell-affiliated hospital**
 - c. Part-time salaried at Cornell
 - d. Part-time salaried at Cornell-affiliated hospital
 - e. Voluntary (self-employed or member of a P.C.)
 - f. Other salaried
 - g. Other non-salaried

I. CURRENT AND PAST INSTITUTIONAL RESPONSIBILITIES

1. Teaching/Mentoring

Teaching:

@ MSKCC:

Body Imaging Fellowship Lecture Series 2012- present

Teaching Weill Cornell residents and MSKCC fellows during daily readouts in plain film, CT and MRI 2012- present

Weill Cornell Resident Noon Conferences:

“MRI Staging of Uterine Tumors” 09/12

“Pitfalls in MRI of the Pelvis” 04/13

Summer Clinical Oncology Research Experience (SCORE) Program
Research Mentor, MSKCC Office of Faculty Development 07/13

@ Medical School, University of Tirana, Albania

Lecturer in Cancer Epidemiology (part-time) Medical School 1995-1996

@ St. John's College University of Cambridge

Anatomy Supervision to Undergraduate Medical Students 2001-2002

@ Addenbrookes Hospital, Cambridge, UK

Cancer Imaging, Lecture to Phase 1 and 3 Medical Students 2002-2012
School of Clinical Medicine, University of Cambridge, UK

Imaging of Endocrine System, Lecture to Phase 1 and 3 Medical 2002-2012
Students, School of Clinical Medicine, University of Cambridge, UK

Imaging of Acute Abdomen, Annual Lecture as Part of Surgery 2003-2005
Residency Program, Addenbrookes Hospital, Cambridge, UK

Imaging in Gynecological Malignancies, Annual Lecture as part of 2005-2008
The Gynecology Oncology Residency Program,
Addenbrookes Hospital, Cambridge, UK

Course Organizer (Genitourinary Imaging), Radiology Residency Program, 2005-2012
Addenbrookes Hospital, Cambridge, UK

Morning Tutorials (1:4 Rota) to Radiology Residency Program 2005-2012
Addenbrookes Hospital, Cambridge, UK

Radiology Evening Tutorials (1:6 Rota) to Medical Students 2005-2012

Addenbrookes Hospital, Cambridge, UK

Anatomy Supervision to Medical Students, 2006-2007
St John's College University of Cambridge, UK

Tutoring

Tutor in Genitourinary, Oncology and MR imaging, 2007-present
European School of Radiology

Tutor, Final Radiology Board Exam Revision Course, 2007-2012
Royal Free Hospital, London, UK

Tutor, Final Radiology Board Exam Revision Course, 2008-2012
Addenbrookes Cambridge, UK

Specialty Director (Radiology) School of Clinical Medicine, 2008-2012
University of Cambridge, UK

Mentoring

@ MSKCC:

- Continuous mentoring of several junior faculty in Body Imaging Service
- Mentoring of several Research and Oncological Imaging Fellows:
 - Irene Burger
 - Olivio Donati
 - Pier Luigi DiPaolo
 - Kate Lampen-Sachar
 - Lizza Lebron-Zapata
 - Elizabeth Sutton
 - Keren Baron
 - Derya Yakar
 - Maura Micco
 - Melvin D'Anastasi
 - Chiara Scelzo
 - Diana Feier
 - Andreas Wibmer
 - Stephanie Nougaret
 - Daisy Huang
 - Edward Lawrence
 - Carlos Nicolau
 - Matthias Benz
 - Eralda Mema
 - Gray Lyons

@ University of Cambridge, UK

Mentoring of several junior faculty, fellows and residents	2005-2012
Support of Master and Doctoral Theses	
Lulit Solomon, MPhil in Epidemiology	1997-1998
Andrew Gill, PhD in Medical Physics	2009-2012
Edward Lawrence, PhD in Radiology	2010-2013

2. Clinical Care

@ MSKCC

Clinical reporting sessions in CT, MRI and PET-CT	2012- present
Gynecology Oncology Tumor Board weekly meeting	2012- present
Pelvic Reconstruction monthly meeting	2012- present
Urology weekly Grand Rounds	2012- present

@ Addenbrookes Hospital, Cambridge, UK

Clinical reporting sessions in US, CT, MRI & PET/CT	2005-2012
Gynecology Oncology Tumor Board (weekly)	2005-2012
Urology Oncology Tumor Board (bi-weekly)	2005-2012
Emergency Oncology Clinical-Radiological Meeting (monthly)	2005-2012
General Urology Clinical-Radiological Meeting (bi-weekly)	2005-2012

3. Administrative Duties

@ MSKCC

Director, Gynecologic Radiology	2012- 2015
Member, Radiology Research Steering Committee	2012- present
Member, Radiology Department Recruitment Committee	2012- present
Member, Radiology Faculty Retreat Committee	2012- 2014
Chair, Search Committee for Head, MRI Physics	2013- 2014
Member, Radiology Faculty Excellence Committee	2013- present
Member, Anti-Angiogenic Agent based Radiosensitization working group	2013- present
Chief, Body Imaging Service	2013- present
Member, Memorial Hospital Alumni Society Executive Council	2015- present

@ Addenbrookes Hospital, Cambridge, UK

Imaging Lead for Gynecology Oncology, East Anglia Cancer Network, UK	2005-2010
Lead Consultant for Gynecology Imaging	2005-2012
Imaging Lead, Gynecology Oncology Tumor Board	2005-2012

@ University of Cambridge, UK
Faculty Board of Clinical Medicine
PET/CT Research Management Committee

2008-2012
2008-2012

a. Research

My research interest has been assessing the role of functional MRI and PET/CT parameters as potential prognostic biomarkers in patients with genito-urinary malignancies. My current research is translational, aimed at evaluating tumor heterogeneity and interactions between imaging phenotype and genotype using new multimodality functional imaging techniques.

@ MSKCC:

IRB protocols:

Principal Investigator:

IRB# 14-061, Benchmarking Intra-tumor Heterogeneity In Ovarian Cancer: Linking In-vivo Imaging Phenotypes With Histology And Genomics

Dates: 03/19/2014-present

PI: Sala, Evis

Co-PI:

IRB# 13-239, Development and Evaluation of Magnetic Resonance Imaging Acquisition and Analysis Methods

Dates: 11/25/2013- present

PI: Akin, Oguz

IRB# 14-172, Evaluation of Treatment Response Using Multiparametric MRI after Prostate Radiotherapy

Dates: 08/21/2014- present

PI: Zelefsky, Michael

IRB# 14-191, Diffusion weighted imaging as a biomarker for early detection of chemotherapy induced cardiotoxicity.

Dates: 10/22/2014-present

PI: Plodkowski, Andrew

IRB# 15-191, Detection of Acid Sphingomyelinase/Ceramide Pathway Activation in Radiotherapy Patients Using Intravoxel Incoherent Motion (IVIM) Diffusion Weighted Magnetic Resonance Imaging and Serum Biomarkers.

Dates: 06/03/2015-present

PI: Vargas, Alberto

Investigator:

IRB# 10-154, A Phase III Randomized Study Comparing Two Dosing Schedules for Hypofractionated Image-Guided Radiation Therapy in Patients with Metastatic Cancer.

Dates: 10/14/2010- present

PI: Zelefsky, Michael

IRB# 12-275, A Phase II Randomized Study: Outcomes after Secondary Cytoreductive Surgery with or without Carboplatin Hyperthermic Intraperitoneal Chemotherapy (HIPEC) followed by Systemic Combination Chemotherapy for Recurrent Platinum Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Dates: 01/05/2013- present

PI: Chi, Dennis

IRB# 14-205, Characterization of Hyperpolarized Pyruvate MRI Reproducibility

Dates: 2015-present

PI: Keshari, Kayvan

IRB# 14-222, Positron Lymphography via Intracervical 18F FDG injection for pre-surgical Lymphatic Mapping in stage 1B1 cervical Cancer and High Grade Endometrial Cancer

Dates: 10/28/2014- present

PI: Abu-Rustum, Nadeem

IRB# 14-110, A Phase 1 Open-label Study of the Selective Inhibitor of Nuclear Export, Selinexor (KPT-330) in Combination with Paclitaxel and Carboplatin in Patients with Advanced Ovarian or Endometrial Cancers

Dates: 06/10 /2014- present

PI: Makker, Vicky

IRB# 14-029, A Phase 1b Dose Escalation Study of Ipafricept (OMP-54F28) in Combination with Paclitaxel and Carboplatin in Patients with Recurrent Platinum-Sensitive Ovarian Cancer

Dates: 04/08 /2014- present

PI: O'Cearbhaill, Roisin

IRB# E15-084, Chemotherapy, Somatic Mutations, Neoantigens, and the Immune Environment in Ovarian Cancer

Dates: 2015-present

PI: Snyder, Alexandra

	<u>Current Percent Effort (%)</u>	<u>Does the activity involve WMC students or researchers? (Y/N)</u>	<u>Does the activity involve MSK trainees or researchers? (Y/N)</u>
Teaching/Mentoring	5%	Y	Y
Clinical Care	60%	Y	Y
Administration	25%	N	Y
Research	10%	N	Y
TOTAL:	100%		

J. RESEARCH SUPPORT

Current:

Stability of Radiomic Features for Abdominal Tumors on Contrast Enhanced CT with Variable Acquisition Parameters

Source: Society of Abdominal Radiology Wylie J. Dodds Research Award

Amount: \$ 15,000

Dates: 2016-2018

PI: Richard Do

Role: Co-PI

Positron lymphography (PLG) sentinel lymph node mapping using PET/MR fusion imaging to guide and improve intraoperative nodal resection.

Source: Molecularly Targeted Intra-Operative Imaging RFA

Amount: \$ 32,899

Dates: 2015-2016

PI: Jennifer Mueller

Role: Co-PI

Pilot Study: Rapid Ovarian Screening with MR Imaging in BRCA Mutation Carriers Undergoing Screening Breast MRI

Source: Radiology Developmental Project Seed Grant

Amount: \$ 29,958

Dates: 2015-2016

PI: Lakhman, Yulia, Mannelli, Lorenzo & Sutton, Elisabeth

Role: Mentor

Benchmarking intra-tumor heterogeneity in high grade serous ovarian cancer (HGSOc): linking in-vivo imaging phenotypes with histology and genomics

Source: Kaleidoscope of Hope Foundation

Amount: \$80,000

Dates: 2013-2016

PI: Vargas, Hebert & Weigelt, Britta

Role: Mentor/Co-investigator

Benchmarking intra-tumor heterogeneity in ovarian cancer: linking in-vivo imaging phenotypes with genomics

Source: Radiology Developmental Project Seed Grant

Amount: \$96,537

Dates: 2013-2016

PI: Vargas, Hebert

Role: Mentor/Co-investigator

Multi parametric imaging and genomics: can we predict clinical outcome in patients with recurrent cervical cancer undergoing pelvic exenteration?

Source: Radiology Developmental Project Seed Grant

Amount: \$76,483

Dates: 2013-2014

PI: Raphael, Barbara
Role: Mentor/Co-investigator

Radiogenomics in Ovarian Cancer: Linking Imaging Phenotypes with Genomics
Source: NHI-CIP TCIA-TCGA multicentre study in ovarian cancer radiogenomics
Dates: 2013-2015
Multi-institutional PI: Sala, Evis (in kind)

Development of hyperpolarized carbon-13 MRI as a novel clinical imaging tool in oncology
Source: Cancer Research UK
Dates: 2014-2017
Amount: £1,400,000 (\$2,100,000)
PI: Gallagher, Ferdia
Role: Collaborator

Research Medical Student Grant - Establishing Tumor Heterogeneity in Patients with Metastatic High-grade Serous Ovarian Cancer (HGSOC): Correlating In Vivo Imaging Phenotypes with Histopathology and Immunohistochemistry
Source: RSNA R&E Foundation
Amount: \$3,000
Dates: 2014
PI: Lawrence, Edward
Role: Mentor

Diffusion weighted imaging as a biomarker for early detection of chemotherapy induced cardiotoxicity.
Source: Society Research Grant
Amount: \$98,937
Dates: 2014-2016
PI: Plodkowski, Andrew
Role: Co-PI

Detection of acid sphingomyelinase/ceramide pathway activation in radiotherapy patients using intravoxel incoherent motion (IVIM) diffusion-weighted magnetic resonance imaging and serum biomarkers.
Source: Imaging and Radiation Sciences Program
Amount: \$98,256
Dates: 2014-2016
PI: Vargas, Hebert
Role: Co-PI

Completed:

Breast Density, Breast Cancer Genetic Markers and Plasma Sex Steroid Levels
Source: Royal College of Radiologists
Amount: £8,000 (\$12,000)
Dates: 2002-2005
PI: Sala, Evis

Evaluation of Early Abdomino-pelvic Computed Tomography in Patients Presenting with Acute Abdominal Pain.

Source: Addenbrooke's Charities
Amount: £8,950 (\$13,425)
Dates: 2004-2005
PI: Sala, Evis

Profiling signatures of chemotherapy response or resistance in ovarian cancer: Correlation with dynamic Magnetic Resonance perfusion imaging.
Source: Cancer Research UK
Amount: £20,000 (\$30,000)
Dates: 2006-2009
PI: Sala, Evis

Cambridge Experimental Cancer Medicine Centre.
Source: Cancer Research UK
Amount: £2,000,000 (\$3,000,000)
Dates: 2007-2012
PI: Caldas, Carlos
Role: Co-investigator (imaging Co-PI)

The role of in vivo molecular and functional magnetic resonance imaging parameters in predicting response and resistance to androgen deprivation therapy in patients with prostate cancer.
Source: Cancer Research UK (Experimental Cancer Medicine Centre)
Amount: £24,000 (\$36,000)
Dates: 2008-2009
PI: Gnanapragasam, Vincent
Role: Co-investigator

A Multicenter Trial to Measure Early Patterns of Change in [18F]-Fluorodeoxyglucose Uptake by PET/CT in Relapsed Ovarian Cancer Patients.
Source: Merck & Co., Inc.
Amount: £589,284 (\$883,926)
Dates: 2009-2010
PI: Brenton, James
Role: Co-investigator

HYPAZ: An investigation in to hypertension induced by pazopanib therapy.
Source: GlaxoSmithKline Research & Development Limited
Amount: £656,955 (\$985,433)
Dates: 2010-2011
PI: Jodrell, Duncan
Role: Co-investigator

Incremental benefit of diffusion weighted MRI versus standard MRI for the pre-operative assessment of tumor stage in prostate cancer.
Source: Cancer Research UK (Experimental Cancer Medicine Centre)
Amount: £40,000 (\$60,000)
Dates: 2010-2011
PI: Gnanapragasam, Vincent
Role: Co-investigator

Neoadjuvant docetaxel prior to radical prostatectomy for high risk localized prostate cancer. Evaluation of biological and functional imaging surrogates of therapy efficacy.

Source: Sanofi-Aventis

Amount: £69,000 (\$103,500)

Dates: 2010-2011

PI: Mazhar, Danish

Role: Co-investigator

Standardization of DWI MRI for quantitative assessment of ovarian cancer and implementation in clinical trials.

Source: Cancer Research UK (The Biomarkers and Imaging Discovery and Development Committee)

Amount: £290,085 (\$435,128)

Dates: 2011-2012

PI: DeSouza, Nandita

Role: Co-investigator

Diagnostic accuracy of MRI, diffusion-weighted MRI, FDG-PET/CT and Fluoro-ethyl-choline PET/CT in the detection of lymph node metastases in surgically staged endometrial and cervical carcinoma.

Source: Cancer Research UK (The Biomarkers and Imaging Discovery and Development Committee)

Amount: £225,698 (\$338,547)

Dates: 2011-2013

PI: Rockall, Andrea

Role: Co-investigator

K. EXTRAMURAL PROFESSIONAL RESPONSIBILITIES

National and International Leadership

Radiological Society of North America

Scientific Committee (Genitourinary) 2006-2012

Radiographics Women's Imaging Panel 2007-2013

Oncologic Imaging and Therapies Task Force 2011-present

Vice-Chair, Oncologic Imaging Refresher Course Committee 2014-2015

Chair, Oncologic Imaging Refresher Course Committee 2015-present

Advisor, Scholar Program 2014-present

Experimental Cancer Medicine Centre (ECMC), CR UK

Imaging Management Committee 2007-2012

American Roentgen Ray Society

Advisory Board Women's Imaging E-Community 2007- present

European Society of Urogenital Radiology

Women's Imaging Subcommittee 2007- present

European Organization for Research and Treatment of Cancer (EORTC)

Imaging Group 2009-2012

<i>International Society for Magnetic Resonance in Medicine (ISMRM)</i>	
Chair of the Body Education Table	2009-2012
Annual Meeting Program Committee	2009-2012
Nominating Committee	2014-present
<i>National Institute of Health Research, Health Technology Assessment Program</i>	
Member, Advisory Panel	2009 -present
<i>American College of Radiology</i>	
American College of Radiology Imaging Network (ACRIN)	2010- present
Gynecology Committee	
<i>European Congress of Radiology</i>	
Genitourinary Scientific Subcommittee	2011- present
<i>National Institute of Clinical Excellence, UK</i>	
Quality Standard for Ovarian Cancer Topic Expert Group	2011-2012
<i>International Cancer Imaging Society</i>	
Member, Board of Trustees	2015-present
Member, Scientific Committee	2014- present
Member, Meeting Program Committee	2014- present
<i>The Society for Abdominal Radiology</i>	
Co-Chair, Uterine and Ovarian Cancer Disease-Focused Panel	2014- present
<u>Grant Reviewer</u>	
National Institute of Health Research, Health Technology Assessment Program, UK	2007- present
Prostate Cancer Charity, UK	2007
Breast Cancer Campaign, UK	2008
The Kay Kendall Leukaemia Fund, UK	2008
Croucher Foundation, Hong Kong	2009
Medical Research Council, Clinical Research Fellowships, UK	2010- present
Worldwide Cancer Research	2016

Keynote Lectures

1. XI Annual Congress of the Spanish Abdominal Radiology Society (SEDIA). October 6-7, 2011, Ibiza, Spain
 - “MRI of the Adnexa”
 - “Staging Ovarian Cancer”
2. The Society for the Advancement of Women’s Imaging Annual Meeting. “Advances in Gynecologic Imaging”. October 18-21, 2012, Chicago, IL
3. The Korean Society of Urogenital Radiology (KSUR) Annual Meeting. April 26, 2014, Seoul, South Korea
 - “Advances in Gynecology Oncology: Combining Morphology and Function”
 - “Staging Ovarian Cancer: What technique is best?”
4. 16th International MRI Symposium. J. Doppman lecture: “MRI of the cervix - combining morphology and function.” January 29-31, 2015, Garmisch-Partenkirchen, Germany
5. Turkish Cancer Society Cancer Awareness Week: Advances in Oncology. “Oncogenetic intratumor variability translated to imaging: Radiomics and Radiogenomics”. April 4, 2015, Istanbul, Turkey.
6. World Molecular Imaging Congress. September 2-5, 2015, Honolulu, Hawaii.
 - Women’s Imaging Spotlight session “Imaging of Gynecologic Tumors: Combining Morphology and Function”
 - Radiogenomics Spotlight session “Radiogenomics, the New Generation Imaging”
7. Italian and Albanian School of Radiology Specialization Magistral Lecture 2015. “Ovarian Cancer: Imaging in Treatment Selection and Planning”. December 17, 2015, Italy.

Refresher Courses

1. American Roentgen Ray Society Annual Meeting. “MRI of malignant neoplasms of uterine corpus and cervix.” April 30-May 5, 2006, Vancouver, Canada
2. European Congress of Radiology. “Benign tumors of the uterus: Detection and characterization.” March 9-13, 2007, Vienna, Austria
3. International Society for Magnetic Resonance in Medicine Annual Meeting. “Uterine malignancies.” May 19-25, 2007, Berlin, Germany
4. European Congress of Radiology. “Normal anatomy (US, CT PET/CT and MRI).” March 9-13, 2008, Vienna, Austria
5. The 95th Scientific Assembly and Annual Meeting of the Radiology Society of North America. “The Added Value of Functional MR Imaging in the Evaluation of Gynecologic Malignancies. November 28-December 4, 2009, Chicago, Illinois
6. International Society for Magnetic Resonance in Medicine Annual Meeting. “Ovarian Masses.”

May 1-7, 2010, Stockholm, Sweden

7. The 96th Scientific Assembly and Annual Meeting of the Radiology Society of North America. “The Added Value of Diffusion-Weighted and Dynamic Multiphase Contrast-enhanced MR Imaging of Gynecologic Malignancies.” November 27-December 3, 2010, Chicago, Illinois
8. European Congress of Radiology. “Staging Ovarian Cancer: What technique is the best?” March 3-8, 2011, Vienna, Austria
9. International Society for Magnetic Resonance in Medicine Annual Meeting. May 7-13, 2011 Montreal, Canada
 - “Malignant Uterine Abnormalities”
 - “MRI of the Ovarian Cancer: Staging, Treatment Response, and Detection of Recurrence”
10. The 97th Scientific Assembly and Annual Meeting of the Radiology Society of North America. “MRI of the Adnexa: the Essentials and beyond”. November 26-December 2, 2011 Chicago, Illinois
11. European Congress of Radiology. “The Acute Female Pelvis” March 1-6, 2012, Vienna, Austria.
12. International Society for Magnetic Resonance in Medicine Annual Meeting. May 7-13, 2012, Melbourne, Australia.
 - “Uterus: gauging depth of invasion”
 - “Anatomy and staging of vulva cancer: all you need to know”
13. The 98th Scientific Assembly and Annual Meeting of the Radiology Society of North America. November 25-30, 2012, Chicago, Illinois,
 - “MRI of the Adnexa: the Essentials and beyond“
 - “GU Diagnosis Live - A Case-based Audience Participation Session“
14. European Congress of Radiology, March 7-11, 2013, Vienna, Austria
 - “The Female Pelvis: An interactive case discussion”
 - “Pitfalls in MRI of the Pelvis”
15. International Society for Magnetic Resonance in Medicine Annual Meeting. “Cervical Carcinoma: Staging & Follow-Up”. April 20-26, 2013 Salt Lake City, Utah,.
16. The 99th Scientific Assembly and Annual Meeting of the Radiology Society of North America. “Interactive game: A Case-based Audience Participation Session (Genitourinary) “. December 1-6, 2013, Chicago, Illinois.
17. European Congress of Radiology. “Pitfalls in MRI of the Pelvis” March 6-10, 2014, Vienna, Austria.
18. International Society for Magnetic Resonance in Medicine Annual Meeting. “Adnexal Masses.” May 10-16, 2014, Milan, Italy
19. The 100th Scientific Assembly and Annual Meeting of the Radiology Society of North America. “Interactive game: A Case-based Audience Participation Session (Genitourinary) “. November 29 - December 5, 2014, Chicago, Illinois.

20. International Society for Magnetic Resonance in Medicine Annual Meeting. “Adnexal Masses.” May 30-June 5, 2015, Toronto, Canada
21. European Congress of Radiology, March 2-6, 2016, Vienna, Austria
 - “Pitfalls in gynaecologic oncologic imaging: how to avoid them and minimise risks”
 - “Imaging of Gynecologic Tumors: Combining Morphology with Diffusion and ADC”

Invited Lectures:

1. The XIV Paulo Foundation International Symposium. October 6-9, 1999 Turku, Finland
 - “The influence of hormone replacement therapy, smoking, and diet on mammographic parenchymal patterns”
 - “Common types of human cancer: current views of prevention, causes, and treatment of breast cancer and prostate cancer”
2. European Congress of Radiology. “Gastrointestinal case presentation in the Junior Image Interpretation Session.” March 4-9, 2004, Vienna, Austria
3. European Association of Veterinary Diagnostic Imaging Annual Meeting. “Advances in body and pelvic magnetic resonance imaging.” November 17, 2005, Cambridge, United Kingdom
4. Gynecology Oncology Master Class, Royal College of Pathologists. “The role of imaging in gynecology oncology”. December 11, 2006, London, United Kingdom
5. The Royal Free Hospital Radiology Academic Program. “MRI of the prostate revisited.” January 18, 2007, London, United Kingdom
6. Visiting Professor Lecture at the Department of Radiology, Georgetown University. “Imaging of malignant uterine tumors”. February 17, 2007, Washington, DC
7. Magnetic Resonance Imaging Symposium. August 30-31, 2007, Helsinki, Finland
 - “Magnetic resonance imaging of prostate cancer”
 - “Magnetic resonance imaging of gynecological malignancies”
8. University of Kyoto. “Magnetic resonance imaging of malignant uterus.” September 25, 2007, Kyoto, Japan
9. Japanese Society for Magnetic Resonance Imaging Annual Meeting.” September 26-29, 2007, Kobe, Japan
 - “Magnetic resonance imaging and spectroscopy of prostate cancer at 1.5 Tesla”
 - “Magnetic resonance imaging of the adnexa”
10. University of Aberdeen. “Evaluation of tumour response to treatment in carcinoma of the cervix.” October 5, 2007, Scotland, United Kingdom
11. UK Magnetic Resonance Clinical Symposium. “Clinical body MRI.” October 30, 2007, London, United Kingdom

12. National Cancer Research Institute Gynaecological Translational Subgroup Workshop. "Functional Imaging in Gynaecology Oncology." April 18, 2008, London, United Kingdom
13. Gynecology Oncology Master Class, British Institute of Radiology. "Cervical cancer: diagnosis, staging, pitfalls and protocols." May 2008 London, United Kingdom
14. European School of Radiology Galen Advanced Course. Women's Cross-Sectional Imaging, "Integrate anatomy (US, CT, MRI, PET/CT)." July 4-5, 2008, Berlin, Germany
15. British Chapter of ISMRM Meeting. "Role of functional MRI in evaluation of response to treatment in gynaecological malignancies." September 4-5, 2008, Newcastle, England
16. Visiting Professor Lecture at the Department of Radiology, McGill University. "MRI of the Adnexa." October 6-7, 2008, Montreal, Canada
17. Visiting Professor Lecture at the Department of Radiology, McGill University. "The role of novel MRI techniques in evaluation of tumour response to treatment." October 6-7, 2008, Montreal, Canada
18. Cambridge Research Institute. "Tumor morphology and heterogeneity: clinical imaging perspective. Joint Workshop on Image Processing in Medicine." November 17, 2008, Cambridge, United Kingdom
19. Master Class in Advanced Cancer Medicine: Gynecological Cancers, Royal Marsden Hospital. "The role of MRI in management of patients with gynaecological tumours." December 8, 2008, London, United Kingdom
20. Fanfani Institute. "Ovarian cancer: screening to staging." February 19, 2009, Florence, Italy
21. GE Healthcare Magnetic Resonance Clinical Symposium. "MRI of benign gynecological conditions." February 28, 2009, Bangalore, India
22. Conference on Women's Health Imaging, Department of Radiodiagnosis and Imaging, Kasturba Hospital. March 1-3, 2009, Manipal, India
 - "Ovarian cancer: from screening to staging"
 - "MRI of malignant uterus: Part I"
 - "MRI of malignant uterus: Part II"
 - "MRI and US in benign gynecological conditions"
23. Society of Abdominal Radiology Annual Scientific Meeting and Educational Course. "MRI of the Uterus." March 15-20, 2009, Maui, Hawaii
24. European School of Radiology Galen Foundation Course. Women's Cross-Sectional Imaging, "Imaging of the pelvis." May 14-16, 2009, Sofia, Bulgaria
25. 16th ESUR Symposium on Urogenital Radiology. "Limitations of female pelvic ultrasound: When do you need MRI/CT?" September 10-13, 2009, Athens, Greece
26. International Meeting on Advances on Urological Cancer. "Imaging in prostate cancer: Evidence and new developments." September 23-24, 2009, Cambridge, United Kingdom

27. European School of Radiology Galen Advanced Course. Women's Cross-Sectional Imaging, Integrate anatomy (US, CT, MRI, PET/CT). September 23-24, 2009, London, United Kingdom
28. Gynecological Cancer Intergroup Meeting. "Imaging as an end point in clinical trials." October 10-11, 2009, Belgrade, Serbia
29. Hospital Clinic Barcelona First Update Meeting: Genitourinary Radiology. February 5, 2010, Barcelona, Spain
 - "Prostate Cancer Imaging"
 - "Value of DWI and DCE in Pelvic Malignancies"
30. East Anglian Radiology Society Annual Meeting. "What's new in gynaecology MRI?" March 17, 2010, Cambridge, United Kingdom
31. Workshop at the 42nd Davos International Diagnostic Course. "Malignant diseases of the female genital tract." March 21-26, 2010, Davos, Switzerland
32. Cancer Imaging Perspectives. "3T MR Imaging for Cancer Assessment." May 21, 2010, London, United Kingdom
33. UK Radiology Congress. "Imaging of the Adnexae." June 7-9, 2010, Birmingham, United Kingdom
34. 13th Biennial Meeting of the International Gynecologic Cancer Society. "The Added Value of Functional Imaging in the Evaluation of Gynecological Malignancies." October 23-26, 2010, Prague, Czech Republic
35. Rochester Roentgen Ray Society. "MRI of the Adnexa: The Essentials and Beyond." December 13, 2010, Rochester, New York
36. Visiting Professor Lecture at the Department of Imaging Sciences, University of Rochester. "MRI of Uterine Malignancies." December 13-14, 2010, Rochester, New York
37. Visiting Professor Lecture at the Department of Radiology, Mount Sinai Medical Center. "MRI of Uterine Malignancies." December 15, 2010, New York, New York
38. Radiology Special Lecture Series, Department of Radiology, Memorial Sloan Kettering Cancer Center. "MRI of Uterine Malignancies." December 21, 2010 New York, New York
39. 14th International MRI Symposium. "Differential Diagnosis of Ovarian Lesions." January 13-15, 2011, Garmisch-Partenkirchen, Germany
40. The Royal Free Hospital Radiology Academic Program. "Clinical Applications of 3T MR Imaging." February 8, 2011, London, United Kingdom
41. European School of Radiology Galen Foundation Course in Oncologic Imaging. "Imaging of Gynaecologic Malignancies." May 26-28, 2011, Vilnius, Lithuania
42. UK Radiology Congress. "Imaging Uterine Masses." June 6-8, 2011, Manchester, United Kingdom

43. Joint Congress of the Society for Urogenital Radiology and European Society for Urogenital Radiology. "Functional Imaging of the Uterine Malignancies: what it adds." October 13-16, 2011, Dubrovnik, Croatia
44. ESMRMB School of MRI Advanced Breast & Female Pelvis MR Imaging. "The Added Value of Functional MRI (DW-MRI and DCE-MRI) in Evaluation of Uterine Malignancies." October 20-22, 2011, Istanbul, Turkey
45. School of Clinical Radiology. "Ovarian Lesions Differential Diagnosis." November 12, 2011, St. Petersburg, Russia
46. British Society of Urogenital Radiology Annual Scientific Meeting. "The Evidence for DWI and Clinical Benefits." November 16-17, 2011, Newcastle upon Tyne, United Kingdom
47. Society of Abdominal Radiology Annual Scientific Meeting and Educational Course. "Uterine Malignancies: The Added Value of MRI." March 26-30, 2012, Phoenix, Arizona
48. European School of Radiology Galen Foundation Course in Oncologic Imaging. "Imaging of Gynecologic Malignancies." June 21-23, 2012, Athens, Greece
49. Visiting Professor Lecture at the Department of Radiology, Catholic University, September 25-26, 2012, Rome, Italy
 - "Imaging of the acute female pelvis"
 - "Uterine malignancies: the added value of MRI in treatment selection and stratification"
 - "The role of MRI in characterization of adnexal lesions"
 - "Staging ovarian cancer: what technique is best?"
50. 3rd International Meeting Imaging in Oncology: The Role of Magnetic Resonance. "Uterine Tumors." September 27-28, 2012, Novara, Italy
51. The Society for the Advancement of Women's Imaging, Annual Meeting, "Revised FIGO Staging of Uterine Malignancies: Implications for MR Imaging". October 18-21, 2012, Chicago, Illinois
52. ACRIN Gynecologic Committee, ECOG-ACRIN meeting. "Functional MRI in gynecologic cancer". November 9-11, 2012, Hollywood, Florida
53. Quizmaster, New York Roentgen Society Meeting, November 12, 2012, New York, New York
54. Grand Rounds Lecture at the Department of Radiology, Brigham and Women's Hospital and Massachusetts General Hospital, Harvard Medical School. "The added value of DWI in evaluation of patients with gynecologic malignancies". December 4-5, 2012 Boston, Massachusetts
55. 15th International MRI Symposium. January 24-26, 2013, Garmisch-Partenkirchen, Germany
 - "MRI in cervical carcinoma "
 - "Endometrial cancer: What is the added value of MRI?"
56. Intensive Pelvic MRI Course. January 14-17, 2013, Melbourne, Australia
 - "GYN malignancies review, FIGO staging and MRI protocol optimization"
 - "GYN benign disease review, indications for MRI compared to US and CT"
 - "MRI of other GU malignancies: bladder and vulvar cancer, what you need to know"

- “Prostate cancer imaging & MRI protocol optimisation”
- 57. Society of Abdominal Radiology Annual Scientific Meeting and Educational Course. “Uterine Malignancies: The added Value of MRI and PET/CT” February 24 - March 1, 2013, Maui, Hawaii
- 58. Imaging and Radiation Sciences Program Annual Scientific Retreat on Tumor Microenvironment: Therapeutic Challenges and Opportunities. “Intravoxel Incoherent Motion (IVIM): implications for cancer imaging”. June 17, 2013, New York, New York
- 59. The Society for the Advancement of Women’s Imaging Annual Meeting. September 26-29, 2013, Chicago, Illinois
 - “Imaging Endometrial Cancer”
 - “Imaging Cervical Cancer”
- 60. New York Roentgen Ray Society, October 9-11, 2013, New York, New York
 - “Uterine malignancies: staging with MRI”
 - “Diffusion Weighted MRI for Tumor Characterization and Response Monitoring”
- 61. Mount Sinai Update 2013: “Body and Non-Invasive Vascular Imaging”, October 15-16, 2013, New York, New York
 - “Adnexal Masses”
 - “Uterine Malignancies”
- 62. World Molecular Imaging Society-Harvard Medical School Course on Molecular Imaging: Advanced Molecular Imaging and its Clinical Translation. “Radiogenomics for Cancer”. October 27-30, 2013, Boston, Massachusetts
- 63. Third Albanian Oncology Association Meeting: “Testicular Tumors and Ovarian Cancer”, November 16, 2013, Tirana, Albania
 - “MRI Characterization of Adnexal Lesions”
 - “Imaging of Ovarian Cancer”
- 64. Intensive Pelvic MRI Course. February 8-10, 2014, Melbourne, Australia
 - “GYN malignancies review, FIGO staging and MRI protocol optimization”
 - “GYN benign disease review, indications for MRI compared to US and CT”
 - “MRI of other GU malignancies: bladder and vulvar cancer, what you need to know”
 - “Prostate cancer imaging & MRI protocol optimization”
- 65. Society of Abdominal Radiology Annual Scientific Meeting and Educational Course. March 23 - 28, 2014, Boca Raton, Florida
 - “Pitfalls in MRI of the Pelvis”
 - “Emerging Role of PET in Advanced Prostate Cancer”
 - “MRI Female Pelvis - Cases for Aces: a case-based review”
- 66. Workshop at the 46th Davos International Diagnostic Course. “Adnexal Diseases.” March 30-April 4, 2014, Davos, Switzerland
- 67. Seoul National University Hospital. “MRI of the Adnexa: The Essentials and Beyond.” April 25, 2014, Seoul, South Korea.

68. The Society for the Advancement of Women's Imaging Annual Meeting. August 21-24, 2014, Chicago, Illinois.
 - “MRI of the Adnexa: The Essentials and Beyond”
 - “Revised FIGO Staging of Uterine Malignancies: Implications for MRI”
 - “The Added Value of DWI in Gynecologic Oncology Imaging”
69. 4th International Meeting Imaging in Oncology: The Evolution. “MRI after Therapy.” September 24-26, 2014, Novara, Italy.
70. International Cancer Imaging Society Meeting and 14th Annual Teaching Course. Hands-on workshop: “Role of Imaging in Ovarian Mass: Imaging in Treatment Selection and Planning with FIGO Update.” October 9-11, 2014, Heidelberg, Germany.
71. Visiting Professor Lecture at the Department of Radiology, Columbia University. “MRI of the Adnexa – the Essentials and Beyond.” December 19, 2014, New York, New York.
72. New York Roentgen Society Meeting. “Ovarian cancer: Role of Imaging in Treatment Selection and Patient Management”. January 12, 2015, New York, New York.
73. 16th International MRI Symposium. “MRI of the Adnexa – the essentials and beyond.” January 29-31, 2015, Garmisch-Partenkirchen, Germany.
74. Intensive Pelvic MRI Course. January 20-22, 2015, Melbourne, Australia
 - “GYN malignancies review, FIGO staging and MRI protocol optimization”
 - “GYN benign disease review, indications for MRI compared to US and CT”
 - “MRI of other GU malignancies: bladder and vulvar cancer, what you need to know”
 - “Prostate cancer imaging & MRI protocol optimization”
75. Society of Abdominal Radiology Annual Scientific Meeting and Educational Course. March 22 - 27, 2015, San Diego, California
 - “MRI Female Pelvis Cases for Aces”
 - “Imaging Treated Prostate Cancer”
76. Turkish Cancer Society Cancer Awareness Week: Advances in Oncology. “Assessment of Uterine Malignancies”. April 4, 2015, Istanbul, Turkey.
77. Barcelona Pelvic MRI Course. April 17-18, 2015, Barcelona, Spain
 - “MRI of Ovarian Diseases: the essentials and beyond”
 - “Endometrial Cancer: the Added Value of MRI”
78. Visiting Professor Lecture at the Department of Radiology, Winthrop University Hospital. “MR Imaging of Adnexal Masses” May 8, 2015, New York, New York.
79. MSKCC Pelvic MRI Course. April 27-29, 2015, New York, New York
 - “How I report a GYN MRI?”
 - “Differentiating benign from malignant disease: how and when not to sit on the fence”
 - “Endometrial Cancer: what is the added value of MRI?”
 - “Rare Gynecologic Cancers: vulva/vagina, gestational trophoblastic disease”

80. Oncologic Imaging Course: The MSK Disease Management Team Approach. “Endometrial Cancer.” May 14-16, 2015, New York, New York.
81. Oncologic Imaging Course: Current Practice and Future Trends in Oncologic Imaging. June 25-27, 2015, Dubrovnik, Croatia.
 - “Differentiating benign from malignant disease: how and when not to sit on the fence”
 - “How does imaging direct management in patients with uterine malignancies?”
82. World Molecular Imaging Congress. “Oncogenetic Intratumor Variability Translated to Imaging: Radiomics and Radiogenomics” September 2-5, 2015, Honolulu, Hawaii.
83. International Cancer Imaging Society Meeting and 15th Annual Teaching Course. Hands-on workshop: “Adnexal Masses and Ovarian Cancer.” October 5-7, 2015, London, UK.
84. Visiting Professor Lecture at the Department of Radiology, University of Cambridge. “Oncogenetic Tumor Heterogeneity Translated to Imaging: Radiomics and Radiogenomics” October 7, 2015, Cambridge, UK.
85. Genetics and Genomics of Gynecologic Cancers October 15-16, 2015, New York, USA.
 - “Ovarian Cancer: The Role of Imaging in Interrogating Tumor Biology and Genomics”
 - “Imaging of Endometrial Cancer: Combining Morphology and Function”
86. Visiting Professor Lecture at the Department of Radiology, Baptist Hospital, Miami, Florida. “Imaging of Gynecologic Tumors: Combining Morphology and Function” January 11, 2016, Miami, Florida.
87. Intensive Pelvic MRI Course. February 19-21, 2015, Melbourne, Australia
 - “Prostate cancer imaging & MRI protocol optimization”
 - “Risk-adapted prostate imaging”
 - “MRI of GYN malignancies”
 - “A logarithmic approach to MRI characterization of adnexal lesions”
 - “MRI of bladder and vulvar cancer, what you need to know”
88. European Congress of Radiology E³ - European Diploma Prep Sessions. “Disorders of the Adnexa” March 2-6, 2016, Vienna, Austria.

Visiting Professorships:

McGill University, Montreal, Canada	2008
Georgetown University, Washington, DC	2008
University of Rochester, New York, NY	2010
Mount Sinai Medical Center, New York, NY	2010
Memorial Sloan Kettering Cancer Center, New York, NY	2010
Catholic University, Rome, Italy	2012
Harvard Medical School, Boston, MA	2012
Columbia University Medical Center, New York, NY	2014
Winthrop University Hospital, New York, NY	2015
University of Cambridge, Cambridge, UK	2015

Baptist Hospital, Miami, Florida	2016
University of Kyoto, Kyoto, Japan	2016

Editorial Board Member

European Radiology	
Editorial Board Member	2008- present
Head of Oncology Section	2011- present
Reports in Medical Imaging	2008- present
European Medical Imaging Review	2010- present

Journal Reviewer

Journal of Medical Screening	2000-2004
Journal of National Cancer Institute	2005
European Radiology	2006- present
Journal of Magnetic Resonance Imaging	2006- present
Magnetic Resonance in Medicine	2007- present
Acta Radiologica	2008
Clinical Oncology	2008-2010
American Journal of Roentgenology	2008- present
Radiographics	2008- present
EURORAD	2008- present
Reports in Medical Imaging	2008- present
European Medical Imaging Review	2010- present
International Journal of Gynecological Cancer	2010- present
Lancet Oncology	2012- present
Radiology	2012- present

L. BIBLIOGRAPHY

1. Peer-reviewed original articles:

1. **Sala E**, Olsen J. Thyroid cancer in age group 0-19: Time trends and temporal changes in radioactive fallout. *Eur J Cancer* 1993; 29:1443-1445.
2. Selenica G, Duffy SW, Sallaku A, **Sala E**. Preoperative therapy in locally advanced rectal cancer. *Journal of BUON* 1998; 4:315-319.
3. **Sala E**, Warren R, McCann J, Duffy S, Day N, and Luben R. Mammographic parenchymal patterns and mode of detection: implications for the Breast Screening Programme. *J Med Screen* 1998;5 (4):207-212.
4. **Sala E**, Warren RML, Day NE. Mammographic parenchymal patterns and breast cancer risk by mode of detection: implications for the Breast Screening Programme. *Eur Radiol* 1999; 9(S1): S10.
5. **Sala E**, Warren R, McCann J, Duffy S, Luben R, Day N. High-risk mammographic parenchymal patterns and anthropometric measures: a case-control study. *Br J Cancer* 1999; Dec 81:1257-1261.
6. **Sala E**, Warren R, Duffy S, Welch A, Luben R, Day N. High-risk mammographic parenchymal patterns and diet: a case-control study. *Br J Cancer* 2000 Jul; 83 (1):121-126.
7. **Sala E**, Warren R, McCann J, Duffy S, Luben R, Day N. High-risk mammographic parenchymal patterns, hormone replacement therapy and other risk factors: a case-control study. *Int J Epidemiol* 2000 Aug;29 (4):629-636.
8. **Sala E**, Warren R, McCann J, Duffy S, Luben R, Day N. Smoking and high-risk mammographic parenchymal patterns: A case control study. *Breast Cancer Res.* 2000;2 (1):59-63.
9. **Sala E**, Solomon L, Warren R, McCann J, Duffy S, Luben R, Day N. Size, node status and grade of breast tumours: association with mammographic parenchymal patterns. *Eur Radiol* 2000;10 (1):157-161.
10. **Sala E**, Warren R, Mccann J, Duffy S, Luben R, Day N. Mammographic parenchymal patterns and breast cancer natural history: a case-control study. *Acta Oncol* 2001;40 (4):461-465.
11. Couto E, Harrison D, Duffy S, Myles J, **Sala E**, Warren R, Day N, Luben R, Chen H. Estimation of disease progression parameters from case-control data: application to mammographic patterns and breast cancer natural history. *J Epidemiol Biostat* 2001;6 (2):235-42.
12. Harrison DA, Duffy SW, **Sala E**, Warren RM, Couteau E, Day NE. Deterministic models for breast cancer progression: Application to the association between mammographic parenchymal patterns and histological grade of breast cancers. *J Clin Epidemiol*, 2002; 55:1113-8.
13. Bjurstam N, Björnelid I, Warwick J, **Sala E**, Duffy SW, Nyström L, Walker N, Cahlin E, Eriksson O, Hafström L, Lingaas H, Mattsson J, Persson S, Rudenstam CM, Salander H, Säve-Söderbergh J, Wahlin T. Age-specific effects of mammography screening: The randomised breast screening trial in Gothenburg. *Am J Onc Rev*, 2003; 2:435-442.

14. Bjurstram N, Björnell I, Warwick J, **Sala E**, Duffy SW, Nyström L, Walker N, Cahlin E, Eriksson O, Hafström L, Lingaas H, Mattsson J, Persson S, Rudenstam CM, Salander H, Säve-Söderbergh J, Wahlin T. The Göteborg Breast Screening Trial. *Cancer*, 2003 May 15;97 (10):2387-96.
15. U-King-Im JM, Trivedi RA, **Sala E**, Graves MJ, Gaskarth M, Higgins NJ, Cross JC, Hollingworth W, Coulden RA, Kirkpatrick PJ, Antoun NM, Gillard JH. Evaluation of carotid stenosis with axial high-resolution black-blood MR imaging. *Eur Radiol*, 2004 Jul;14 (7):1154-61.
16. **Sala E**, Coulden RA, Goddard M. Incidental detection of an autonomous nodule in retrosternal goitre on F-18 FDG positron emission tomography. *Clin Nucl Med*, 2004 Nov; 29 (11):732-3.
17. **Sala E**, Coulden RA. Incidental bronchogenic cyst detected on ¹⁸F-FDG positron emission tomography. *Clin Nucl Med*, 2004; 29:494-495.
18. Atkinson C, Warren RM, **Sala E**, Dowsett M, Dunning AM, Healey CS, Runswick S, Day NE, Bingham SA. Red-clover-derived isoflavones and mammographic breast density: a double blind, randomized, placebo-controlled trial. *Breast Cancer Res*, 2004;6 (3):R170-9.
19. Jardine VL, **Sala E**, Lomas DJ. MR Colonography: Baseline appearance of the unprepared rectosigmoid. *Br J Radiol*, 2005 Mar; 78 (927):202-6.
20. Lomas DJ, Habib S, Joubert I, **Sala E**, Graves, MJ. CO₂ as a distending medium for gastric and small bowel MRI. *Eur Radiol*, 2005 Apr; 15 (4):672-6.
21. Beadsmoore CJ, Cheow HK, **Sala E**, Lomas DJ, Gibbs P, Save V, Balan KK, Alison MED. Hepatocellular carcinoma tumour thrombus in a re-canalised paraumbilical vein: detection by ¹⁸F-FDG PET. *Br J Radiol*, 2005 Sep; 78(933):841-4.
22. Huzjan R, **Sala E**, Hricak H. Magnetic resonance imaging and magnetic resonance spectroscopic imaging of prostate cancer. *Nat Clin Pract Urol*. 2005 Sep; 2 (9):434-42.
23. **Sala E**, Eberhardt SC, Akin O, Moskowitz CS, Onyebuchi CN, Kuroiwa K, Ishilln N, Zelefsky MJ, Eastham JA, Hricak H. Endorectal MR Imaging prior to salvage prostatectomy: tumor localization and staging. *Radiology*, 2006 Jan;238 (1):176-83.
24. **Sala E**, Akin O, Moskowitz C, Eisenberg H, Kuroiwa K, Ishilln NM, Rajashankar B, Scardino PT, Hricak H. Endorectal MR imaging in the evaluation of seminal vesicle invasion: diagnostic accuracy and multivariate feature analysis. *Radiology*. 2006 Mar; 238 (3):929-37.
25. Graves MJ, Kershaw LE, Black RT, **Sala E**, Skinner J, Lomas DJ. Interactive Magnetic Resonance Cholangiopancreatography (MRC) with adaptive averaging. *J Magn Reson Imaging*. 2006 Apr; 23 (4):529-33.
26. Akin O, **Sala E**, Moskowitz C, Eisenberg H, Kuroiwa K, Ishilln N, Scardino P, Hricak H. Transition zone prostate cancers: features, detection, localization, and staging at endorectal MR imaging. *Radiology*. 2006 Jun; 239 (3):784-92.

27. Kataoka M, Warren R, Luben R, Camus J, Denton E, **Sala E**, Day N, Khaw KT. How predictive is breast arterial calcification of cardiovascular disease and risk factors when found at screening mammography? *AJR Am J Roentgenol*. 2006 Jul; 187 (1):73-80.
28. **Sala E**, Graves MJ, Abubacker Z, Kershaw LE, Black RT, Skinner J, Beavon R, Lomas DJ. High resolution Magnetic Resonance Cholangiography (MRC) with adaptive averaging: diagnostic performance evaluation. *Clin Radiol*, 2006 Sep; 61 (9):766-70.
29. Warren R, Skinner J, **Sala E**, Denton E, Dowsett M, Folkerd E, Healey CS, Dunning A, Doody D, Ponder B, Luben RN, Day NE, Easton D. Associations between mammographic density, circulating sex hormones and polymorphisms in sex hormone metabolism genes in post-menopausal women. *Cancer Epidemiol Biomarkers Prev*, 2006 Aug; 15 (8):1502-8.
30. Gallagher FA, Gopalan D, **Sala E**. Ankylosing spondylitis: an unusual cause for complete heart block (2005:10b). *Eur Radiol*, 2006; 16:244-6.
31. Zahra MA, Hollingsworth, K, **Sala E**, Brenton J, Lomas DJ, Tan LT. Dynamic contrast enhanced magnetic resonance imaging as a predictor of tumour response to radiotherapy. *Lancet Oncology*. 2007 Jan; 8(1):63-74.
32. Koo BC, **Sala E**, Hackett GA, Shaw A. A pregnant lady with recurrent vaginal bleeding (2007:3b). *Placenta praecreta*. *Eur Radiol*, 2007 Jun; 17 (6):1647-9.
33. **Sala E**, Watson CJ, Beadsmoore C, Groot-Wassink T, Fanshawe TR, Smith JC, Bradley A, Palmer CR, Shaw A, Dixon AK. A randomized, controlled trial of routine early abdominal computed tomography in patients presenting with non-specific acute abdominal pain. *Clin Radiol*. 2007 Oct; 62 (10):961-9.
34. Warren R, Thompson D, del Frate C, Cordell M, Highnam, R, Tromans C, Warsi I, Ding J, **Sala E**, Estrella F, Solomonides AE, Odeh M, McClatchey R, Bazzochi M, Amendolia SR, Brady M. A comparison of some anthropometric parameters between an Italian and a UK population: "proof of principle" of a European project using MammoGrid. *Clin Radiol*, 2007 Nov; 62 (11):1052-60.
35. Zahra MA, **Sala E**, Lomas DJ, Crawford RAF, Brenton J, Arends M, Tan LT. The predictive role of functional imaging in cervix cancer. *Clin Oncol*, 2007:19:S51.
36. Addley H, Grant LA, Crawford R, **Sala E**: Medical image. A prepubescent mass. Swyer syndrome with a bilateral dysgerminoma. *N Z Med J*, 2008 Apr 4; 121 (1271):117-8.
37. Kataoka M, Atkinson C, Warren R, **Sala E**, Day NE, Hingham R, Warsi I, Bingham SA. Mammographic density using two computer-based methods in an isoflavone trial. *Maturitas*. 2008 Apr 20;59 (4):350-7.
38. Hugill J, **Sala E**, Hollingsworth KG, Lomas DJ. MR Sialography: the effect of a sialogogue and ductal occlusion in volunteers. *Br J Radiol*. 2008 Jul; 81 (967):583-6.
39. Akin O, **Sala E**, Moskowitz CS, Ishill N, Soslow RA, Chi DS, Hricak H. Perihepatic metastases from ovarian cancer: sensitivity and specificity of CT for the detection of metastases with and those without liver parenchymal invasion. *Radiology*. 2008 Aug; 248 (2):511-7.

40. Ringl H, Schernthaner R, **Sala E**, El-Rabadi K, Weber M, Schima W, Herold CJ, Dixon AK. Lossy three-dimensional JPEG2000 compression of abdominal CT images in patients with acute abdominal complaints: effect of compression ratio on diagnostic confidence and accuracy. *Radiology*, 2008 Aug; 248 (2):476-84.
41. Soh E, Eleti A, Jimenez-Linan M, Arends MJ, Latimer J, **Sala E**. Magnetic resonance imaging findings of tamoxifen-associated uterine mullerian adenosarcoma. *Acta Radiol* 2008 Sep; 49 (7):848-51.
42. Griffin N, Grant LA, Freeman SJ, Jimenez-Linan M, Berman LH, Earl H, Ahmed AA, Crawford R, Brenton J, **Sala E**. Image guided biopsy in patients with suspected ovarian carcinoma: a safe and effective technique? *Eur Radiol*. 2009 Jan; 19 (1):230-5.
43. **Sala E**, Crawford R, Senior E, Shaw A, Simcock B, Vrotsou K, Palmer C, Rajan P, Joubert I, Lomas D. Added value of dynamic contrast-enhanced magnetic resonance imaging in predicting advanced stage disease in patients with endometrial carcinoma. *Int J Gynecol Cancer*. 2009 Jan; 19(1):141-6.
44. Shah AK, **Sala E**, Staiano JJ. If the scan fits — evacuate! *J Plast Reconstr Aesthet Surg* 2009 Apr; 62 (4):554-5.
45. Zahra MA, Tan LT, Priest AN, Graves MJ, Arends M, Crawford RA, Brenton JD, Lomas DJ, **Sala E**. Semiquantitative and quantitative dynamic contrast enhanced magnetic resonance imaging predicts radiation response in cervix cancer. *Int J Radiat Oncol Biol Phys*. 2009 Jul 1; 74 (3):766-73.
46. McClean MA, Priest AN, Joubert I, Lomas DJ, Kataoka MJ, Earl H, Crawford R, Brenton JD, Griffiths JR, **Sala E**. Metabolic characterisation of primary and metastatic ovarian cancer by ¹H MRS in vivo at 3 Tesla. *Mag Res Med*, 2009 Oct; 62(4):855-61.
47. **Sala E**, Beadsmoore C, Gibbons D, Shaw A, Gaskarth M, Groot-Wassink T, Watson C, Dixon AK. Unexpected changes in clinical diagnosis: early abdomino-pelvic computed tomography compared with clinical evaluation. *Abdominal Imaging*, 2009 Nov; 34 (6):783-7.
48. **Sala E**, Priest AN, Kataoka M, Graves MJ, McClean MA, Joubert I, Griffiths JR, Crawford RA, Jimenez-Linan M, Earl HM, Brenton JD, Lomas DJ. Apparent diffusion coefficient and vascular signal fraction measurements with magnetic resonance imaging: feasibility in metastatic ovarian cancer at 3T: technical development. *Eur Radiol*. 2010 Feb; 20 (2):491-6.
49. Kataoka MY, **Sala E**, Baldwin P, Reinhold C, Farhadi A, Hudolin T, Hricak H. The accuracy of magnetic resonance imaging in staging of vulvar cancer: a retrospective multi-centre study. *Gynecol Oncol*, 2010 Apr; 117 (1):82-7.
50. Priest AN, Gill, AB, Kataoka M, McClean MA, Joubert I, Graves MJ, Griffiths JR, Crawford RA, Earl H, Brenton JD, Lomas DJ, **Sala E**. Dynamic contrast-enhanced MRI in ovarian cancer: initial experience at 3 Tesla in primary and metastatic disease. *Mag Res Med*, 2010 Apr; 63 (4):1044-9.
51. Grant L, Moyle P, Griffin N, Williams M, **Sala E**, Vasconcelos J, Dixon A. Visceral abdominal obesity - is there an increased prevalence in men presenting with testicular teratoma? *Acta Radiol*, *Acta Radiol*. 2010 Jul; 51 (6):687-92.

52. **Sala E**, DeSouza N, Lee S, Atri M, Hricak H. Ovarian Cancer: the role of functional imaging as an endpoint in clinical trials. *Int J Gynecol Cancer*. 2010 Aug; 20(6):971-8.
53. Mannelli L, Patterson AJ, Zahra M, Priest AN, Graves MJ, Lomas DJ, Tan LT, Crawford R, Brenton J, **Sala E**. Evaluation of nonenhancing tumor fraction assessed by dynamic contrast-enhanced MRI subtraction as a predictor of decrease in tumor volume in response to chemoradiotherapy in advanced cervical cancer. *AJR Am J Roentgenol*. 2010 Aug; 195 (2):524-7.
54. **Sala E**, Kataoka M, Pandit-Taskar N, Ishill N, Mironov S, Mosckowitz CS, Mironov O, Collins MA, Chi DS, Larson S, Hricak H. Recurrent ovarian cancer: contrast-enhanced CT and PET/CT can accurately localize tumor recurrence and to predict patients' survival. *Radiology*. 2010 Oct; 257(1):125-34.
55. Addley HC, Crawford RAF, Jimenez-Linan M, **Sala E**. Primary neuroendocrine carcinoma of the Bartholin's gland: magnetic resonance imaging findings with pathologic correlation. *Eur J Radiol* 2010; 75:e37-e38.
56. Cooke SL, Temple J, MacArthur S, Zahra MA, Tan LT, Crawford RA, Ng CK, Jimenez-Linan M, **Sala E**, Brenton JD. Intra-tumour genetic heterogeneity and poor chemoradiotherapy response in cervical cancer. *Br J Cancer*. 2011 Jan 18; 104(2):361-8.
57. Beddy P, Rangarajan RD, Kataoka M, Moyle P, Graves MJ, **Sala E**. T1-weighted fat-suppressed imaging of the pelvis with a dual-echo Dixon technique: initial clinical experience. *Radiology*. 2011 Feb; 258(2):583-9.
58. **Sala E**, Mannelli L, Yamamoto K, Griffin M, Griffin N, Grant L, Parker R, Crawford R. The value of postoperative/pre-adjuvant chemotherapy computed tomography in the management of patients with ovarian cancer. *Int J Gynecol Cancer* 2011 Feb; 21(2): 296-301.
59. **Sala E**, Rockall A, Kubik-Huch RA. Advances in magnetic resonance imaging of endometrial cancer. *Eur Radiol*. 2011 Mar; 21(3):468-73.
60. McLean MA, Barrett T, Gnanapragasam VJ, Priest AN, Joubert I, Lomas DJ, Neal DE, Griffiths JR, **Sala E**. Prostate cancer metabolite quantification relative to water in 1H-MRSI in vivo at 3 Tesla. *Magn Reson Med*. 2011 Apr; 65(4):914-9.
61. Balleyguier C, **Sala E**, Da Cunha T, Bergman A, Brkljacic B, Danza F, Forstner R, Hamm B, Kubik-Huch R, Lopez C, Manfredi R, McHugo J, Oleaga L, Togashi K, Tsili A, Kinkel K. Staging of uterine cervical cancer with MRI: Guidelines of the European Society of Urogenital Radiology. *Eur Radiol*. 2011 May; 21(5):1102-10.
62. Neale H, Housden R, Crawford R, Treece G, **Sala E**, Gee A, Prager R. A pilot study using transvaginal real-time ultrasound elastography to evaluate the postmenopausal endometrium. *Ultrasound Obstet Gynecol*. 2011 Aug; 38(2):235-6.
63. Gourtsoyianni S, Hudolin T, **Sala E**, Goldman D, Bochner BH, Hricak H. MRI at the completion of chemoradiotherapy can accurately evaluate the extent of disease in women with advanced urethral carcinoma undergoing anterior pelvic exenteration. *Clin Radiol* 2011 Nov; 66(11):1072-8.

64. Barrett T, Gill AB, Kataoka MY, Priest AN, Joubert I, McLean MA, Graves MJ, Stearn S, Lomas DJ, Griffiths JR, Neal D, Gnanapragasam VJ, **Sala E**. DCE-MRI and DW-MRI in Monitoring Response to Androgen Deprivation Therapy in Patients with Prostate Cancer: A Feasibility study. *Magn Res Med* 2012; 67(3):778-85.
65. Griffin N, Addley H, **Sala E**, Shaw A, Grant LA, Eldaly H, Davies SE, Prevost T, Alexander GJ, Lomas DJ. Vascular invasion in hepatocellular carcinoma: Is there a correlation with MRI? *Br J Radiol.* 2012 Jun; 85(1014):736-44.
66. Beddy P, Moyle P, Kataoka MY, Yamamoto AK, Joubert I, Lomas DJ, Crawford R, **Sala E**. Comparison of diffusion weighted MRI and dynamic contrast enhanced MRI in evaluating the depth of myometrial invasion and overall staging in endometrial cancer. *Radiology.* 2012; 262(2):530-537.
67. Mironov O, Mironov S, **Sala E**, Pannu H, Zheng J, Moskowitz CS, Hricak H, Chi DS. Comparison between computed tomography and video-assisted thoracic surgery findings in patients with advanced epithelial ovarian carcinoma. *Journal of Gynecologic Oncology* 2012; 22(4):260-8.
68. **Sala E**, Kataoka MY, Priest AN, Gill AB, McClean MA, Joubert I, Graves MJ, Crawford R, Jimenez-Linan M, Earl H, Hodgkin C, Griffiths JR, Lomas DJ, Brenton JD. Multi-parametric MRI of advanced ovarian cancer demonstrates response- and metastasis-specific effects. *Radiology* 2012; 263:149-159.
69. Peters NHGM, Patterson AJ, Horan G, Gregory D, and **Sala E**. Assessment of ovarian movement on consecutive pelvic MRI examinations in patients with gynaecologic malignancies: what is the planning organ at risk volume for radiotherapy? *Br J Radiol.* 2012; 85:1407-1414.
70. Annamalai AK, Cluroe AD, **Sala E**, Park SM, MacDougall J, Hughes IA, Simpson HL. Puberty reveals a familial disorder of sex development. *Endocrine.* 2012; 42:453-5.
71. Burger IA, Vargas HA, Donati OF, Andikyan V, **Sala E**, Gonen M, Goldman D, Chi DS, Schoder H, Hricak H. The Value of 18F-FDG PET/CT in recurrent gynecologic malignancies prior to pelvic exenteration. *Gynecol Oncol* 2013; 129:586-592.
72. Donati OF, Lakhman Y, **Sala E**, Burger IA, Vargas HA, Goldman D, Andikyan V, Park, KJ, Chi DS, Hricak H. Role of preoperative MR imaging in the evaluation of patients with persistent or recurrent gynaecological malignancies before pelvic exenteration. *Eur Radiol.* 2013, 23:2906-2915.
73. Vargas HA, Burger IA, Donati OF, Andikyan V, Lakhman Y, Goldman, Schoder H, Chi DS, **Sala E**, Hricak H. MRI/PET provides a roadmap for surgical planning and serves as a predictive biomarker in patients with recurrent gynecological cancers undergoing pelvic exenteration. *Int J Gynecol Cancer.* 2013, 8:1512-1519.
74. Milgrom SA, Vargas HA, **Sala E**, Kelvin JF, Hricak H, Goodman KA. Acute effects of pelvic irradiation on the adults uterus revealed by dynamic contrast-enhanced MRI. *Br J Radiol.* 2013 Nov;86(1031) DOI: 10.1259/bjr.20130334.
75. Rockall AG, Avril NE, Lam R, Iannone R, David Mozley DP, Parkinson C, Bergstrom D, **Sala E**, Sarker S, McNeish IA, Brenton JD. Repeatability of quantitative FDG-PET/CT and contrast enhanced CT in recurrent ovarian carcinoma: test retest measurements for tumor FDG uptake, diameter and volume. *Clin Cancer Res* 2014; 20(10); 1–10.

76. Lawrence EM, Gallagher FA, Barrett T, Warren AY, Priest AN, Goldman D, **Sala E***, Gnanapragasam VJ*. Pre-operative 3-tesla diffusion weighted MRI for the qualitative and quantitative assessment of extracapsular extension in patients with intermediate or high-risk prostate cancer. *Am J Roentgen* 2014;203(3):W280-6.
77. Lawrence EM, Tang SYW, Barrett T, Koo B, Goldman DA, Warren AY, Axell R, Doble A, Gallagher FA, Gnanapragasam VJ, Kastner C, **Sala E**. Prostate cancer: Performance characteristics of combined T2W and DW-MRI scoring in the setting of template transperineal rebiopsy using MR-TRUS fusion. *Eur Radiol* 2014;24(7):1497-505.
78. Miccò M, Vargas HA, Burger IA, Kollmeier, MA, Goldman DA, Park KJ, Abu-Rustum NR, Hricak H, **Sala E**. Combined pre-treatment MRI and 18F-FDG PET/CT parameters as prognostic biomarkers in patients with cervical cancer. *Eur J Radiol* 2014;83(7):1169-76.
79. Grisham RN, Iyer G, **Sala E**, Zhou Q, Iasonos A, DeLair D, Hyman DM, Aghajanian C. Bevacizumab shows activity in patients with low-grade serous ovarian and primary peritoneal cancer. *Int J Gynecol Cancer* 2014;24(6):1010-4.
80. Gondo T, Hricak H, **Sala E**, Zheng J, Moskowitz CS, Bernstein M, Eastham JA, Vargas HA. Multiparametric 3T MRI for the prediction of pathological downgrading after radical prostatectomy in patients with biopsy-proven Gleason score 3 + 4 prostate cancer. *Eur Rad* 2014; 24 (12):3161-3170.
81. Vargas HA, Donati OF, Wibmer A, Goldman DA, Mulhall JP, **Sala E**, Hricak H. Association between penile dynamic contrast-enhanced MRI derived quantitative parameters and self-reported sexual function in patients with newly diagnosed prostate cancer. *J Sex Med* 2014;11(10):2581-8.
82. Di Paolo PL, Vargas HA, Karlo KA, Lakhman Y, Zheng J, Moskowitz CS, Al-Ahmadie HA, **Sala E**, Bochner BH, Hricak H. Intra-diverticular bladder cancer: CT imaging features and their association with clinical outcomes. *Clinical Imaging* 2014; 39(1):94-98.
83. Vargas HA, Micco M, Hong S, Goldman DA, Dao, F, Weigelt B, Soslow RA, Hricak H, Levine DA, **Sala E**. Association between morphologic computed tomography imaging traits and prognostically relevant gene signatures in women with high-grade serous ovarian cancer: A Hypothesis Generating Study. *Radiology*. 2015 Mar; 274(3):742-51.
84. Schwarz RF, Ng CKY, Cooke SL, Newman S, Temple J, Piskorz AM, Gale D, Sayal K, Murtaza M, Baldwin PJ, Rosenfeld N, Earl HE, **Sala E**, Jimenez-Linan M, Parkinson CA, Markowitz F, Brenton JD. Spatial and temporal heterogeneity in high-grade serous ovarian cancer: a phylogenetic reconstruction. *PLoS Med*. 2015 Feb 24; 12(2).
85. Lakhman Y, Katz SS, Goldman DA, Yakar D, Vargas HA, Sosa R, Micco M, Soslow R, Hricak H, Abu-Rustum NR, **Sala E**. Diagnostic performance of ct for preoperative staging of patients with non-endometrioid carcinomas of the uterine corpus. *Annals of Surgical Oncology* 2015 DOI: 10.1245/s10434-015-4410-x).
86. Wibmer A, Vargas HA, Donahue T, Zheng J, Moskowitz C, Eastham J, **Sala E**, Hricak H. Diagnosis of Extracapsular Extension of Prostate Cancer on Prostate MRI: Impact of Second-Opinion Readings by Sub-Specialized Genitourinary Oncologic Radiologists. *AJR Am J Roentgenol*. 2015 Jul; 205(1):W73-8.

87. Wibmer A, Hricak H, Gondo T, Matsumoto K, Veeraraghavan H, Fehr D, Zheng J, Moskowitz C, Fine S, Reuter VE, Eastham J, **Sala E**, Vargas HA. Haralick Texture Analysis of prostate MRI: differentiating normal prostate from clinically significant prostate cancer and associations with cancer aggressiveness. *Eur Radiol* 2015; 25(10):2840-50.
88. Fehr D, Veeraraghavan H, Wibmer A, Gondo T, Matsumoto K, Vargas HA, **Sala E**, Hricak H, Deasy JO. Automatic classification of prostate cancer Gleason score from multi-parametric Magnetic Resonance Images *PNAS* 2015; 112(46):E6265-73.
89. Vargas HA, Burger IA, Goldman DA, Micco M, Sosa RE, Weber W, Chi DS, Hricak H, Levine DA, **Sala E**. Volume-based quantitative FDG PET/CT metrics and their association with optimal debulking and progression-free survival in patients with recurrent ovarian cancer undergoing secondary cytoreductive surgery. *Eur Radiol* 2015 DOI 10.1007/s00330-015-3729-9.
90. Nougaret S, Reinhold C, Al Sharif SS, Addley H, Hoetker A, Chong J, Arceneau J, Guiu1 B, Molinari N, **Sala E**. Combined MR volumetry and diffusion weighted imaging in the assessment of myometrial invasion, lymphovascular space invasion and tumor grade in endometrial cancer. *Radiology*. 2015 Sep; 276(3):797-808.
91. Burger IA, Goldman DA, Vargas AH, Kattan MW, Yu C, Kou L, Andikyan V, Chi DS, Hricak HH, **Sala E**. Incorporation of postoperative CT data into clinical models to predict 5-year overall and recurrence free survival after primary cytoreductive surgery for advanced ovarian cancer. *Gynecol Oncol*. 2015 Sep;138(3):554-9.
92. Lakhman Y, Yakar D, Goldman DA, Katz SS, Vargas HA, Micco M, Zheng J, Moskowitz CS, Soslow R, Hricak H, Abu-Rustum NR, **Sala E**. Preoperative CT-based nomogram for predicting overall survival in women with non-endometrioid carcinomas of the uterine corpus. *Abdominal Imaging* 2015; 40:1761-8.
93. Barrett T, Priest AN, Lawrence EML, Goldman DA, Warren AY, Gnanapragasam VJ, **Sala E**, Gallagher FA. The ADC ratio of tumor to normal prostate as a method for quantifying diffusion weighted imaging of the prostate. *Am J Roentgen* 2015; 205:W585–W593.
94. **Sala E**, Micco M, Burger IA, Yakar D, Kollmeier M, Goldman DA, Gonen M, Park KJ, Abu-Rustum NR, Hricak H, Vargas HA. Complementary prognostic value of pelvic MRI and whole-body FDG PET/CT in the pretreatment assessment of patients with cervical cancer. *Int J Gynecol Oncol* 2015;25(8): 1461–1467.
95. Vargas HA, Hötker AM, Goldman DA, Moskowitz CS, Gondo T, Matsumoto K, Ehdaie B, Woo S, Fine SW, Reuter VE, **Sala E**, Hricak H. Updated prostate imaging reporting and data system (PIRADS v2) recommendations for the detection of clinically significant prostate cancer using multiparametric MRI: critical evaluation using whole-mount pathology as standard of reference. *Eur Radiol*. 2015 Sep 22. [Epub ahead of print] PMID: 26396111
96. Lakhman Y, D’Anastasi M, Micco M, Scelzo C, Vargas AH, Nougaret S, Sosa RE, Chi D, Abu-Rustum N, Hricak H, **Sala E**. Second-opinion interpretations of gynecologic oncologic MRI examinations by sub-specialized radiologists influence patient care. *Eur Radiol* 2015 DOI: 10.1007/s00330-015-4040-5.

97. Grisham RN, Sylvester B, Won H, Mcdermott G, DeLair D, Ramirez R, Yao Z, Shen R, Dao F, Bogomolny F, Makker V, **Sala E**, Hyman DM, Socci N, Viale A, Gershenson DM, Farley J, Levine DA, Rosen N, Berger MF, Spriggs D, Aghajanian C, Solit DB, Iyer G. Extreme outlier analysis identifies occult MAP kinase pathway mutations in patients with low-grade serous ovarian cancer. *J Clin Oncol* 2015; DOI: 10.1200/JCO.2015.62.4726.
98. Yasser H, Ducie JA, Arnold AG, Kauff ND, Vargas AH, **Sala E**, Levine DA, Soslow R. Invasion Patterns of Metastatic Extruterine High Grade Serous Carcinoma with BRCA Germline Mutation and Correlation with Clinical Outcomes. *Am J Surg Pathol* 2015; PMID:26574845
99. Robertson NL, Hricak H, Sonoda Y, Sosa R, Benz M, Lyons G, Abu-Rustum N, **Sala E**, Vargas AH. The impact of FDG-PET/CT in the management of patients with vulvar and vaginal cancer. *Gynec Oncol* 2015 DOI: 10.1016/j.ygyno.2016.01.011.
100. Sharma S, Sevak KK, Monette S, Carlin SD, Knight JC, Wuest FR, **Sala E**, Zeglis BM, Lewis JS. Preclinical 89Zr-immunPET of high grade serous ovarian cancer and lymph node metastasis. *J Nuc Med* 2016 (in press).

2. Reviews, books and book chapters

Reviews:

1. Expert Panel on Women's imaging: Hricak H, Akin O, **Sala E**, Fleischer AC, Böhm-Vélez M, Fishman EK, Mendelson E, Thurmond A, and Goldstein S. American College of Radiology. "Endometrial Cancer of the Uterus," ACR Appropriateness Criteria™, 2005. http://www.acr.org/ac_pda.
2. Expert Panel on Women's Imaging: Hricak H, Akin O, **Sala E**, Fleischer AC, Böhm-Vélez M, Fishman EK, Mendelson E, Thurmond A, Goldstein S. American College of Radiology. "Invasive cancer of the cervix," ACR Appropriateness Criteria™, 2005. http://www.acr.org/ac_pda.
3. **Sala E**. Diagnosis of ovarian cancer. Making the Best Use of a Department of Clinical Radiology. The Royal College of Radiologists, U.K. 2006.
4. **Sala E**. Follow-up of ovarian cancer. Making the Best Use of a Department of Clinical Radiology. The Royal College of Radiologists, U.K. 2006.
5. **Sala E**, Wakely S, Senior E, Lomas DJ. MRI of malignant neoplasms of uterine corpus and cervix. *Am J Roentgenol* 2007 Jun; 188(6):1577-87.
6. Griffin N, Grant LA, **Sala E**. Magnetic resonance imaging of vaginal and vulval pathology. *Eur Radiol*, 2008; 18:1269-1280.
7. **Sala E**. Magnetic resonance imaging of female pelvis. *Semin Roentgenol* 2008; 43:290-302.
8. Freeman S, Hampson F, Addley H, Moyle P, **Sala E**. Imaging of the female pelvis. *Obst Gynecol and Rep Med*, 2009; 19:271-281.

9. Addley H, **Sala E**. The role of imaging in advanced endometrial carcinoma. *Eur Oncol*, 2009; 5:68-70.
10. Moyle PM, Kataoka MY, Nakai A, Takahata A, Reinhold C, **Sala E**. Non-ovarian cystic lesions of the pelvis. *Radiographics*, 2010; 30 921-938. 2010 Jul-Aug; 30(4):921-38.
11. Addley HC, Vargas HA, Moyle PL, Crawford R, **Sala E**. Pelvic imaging following chemotherapy and radiation therapy for gynecologic malignancies. *Radiographics*. 2010 Nov; 30(7):1843-56 .
12. Forstner R, **Sala E**, Kinkel K, Spencer JA. ESUR guidelines: ovarian cancer staging and follow-up. *Eur Radiol* 2010; 20:2773-2780.
13. Grant LA, **Sala E**, Griffin N. Congenital and acquired abnormalities of the vulva and vagina on magnetic resonance imaging: a pictorial review. *Semin Ultrasound CT MR* 2010; 31(5):347-62.
14. Beddy P, Kogan MT, **Sala E**, Griffin N. Magnetic resonance imaging for acute abdominal pain in pregnancy. *Semin Ultrasound CT MR* 2010; 31(5):433-41.
15. Moyle PM, Addley HC, **Sala E**. Radiological staging of ovarian carcinoma. *Semin Ultrasound CT MR* 2010; 31(5):388-98.
16. Griffin N, Grant LA, **Sala E**. Adnexal masses: characterization and imaging strategies. *Semin Ultrasound CT MR* 2010; 31(5):330-46.
17. **Sala E**, Rockall A, Rangarajan D, Kubik-Hunch RA. The role of dynamic contrast-enhanced and diffusion weighted magnetic resonance imaging in the female pelvis. *Eur J Radiol* 2010; 76:367–385.
18. deSouza NM, **Sala E**. Standardizing the use of functional MRI in prostate cancer. *Nat Rev Urol* 2011; 8:127–129.
19. Balleyguier C, **Sala E**, Kinkel K. Staging uterine cervical cancer with magnetic resonance imaging. *Hosp Imag Radiol Europe* 2011; 6:32-35.
20. **Sala E**, Vargas HA, Wassberg C, Kyriazi S, deSouza NM. The role of functional MRI and PET/CT in evaluation of patients with primary and recurrent ovarian cancer. *Imaging in Medicine* 2011; 3:333-343.
21. Beddy P, Rangarajan RD, **Sala E**. Role of MRI in Intracavitary brachytherapy for cervical cancer: What the radiologist needs to know. *AJR Am J Roentgenol*. 2011 Mar; 196(3):W341-7.
22. Beddy P, O'Neill AC, Yamamoto AK, Addley HC, Reinhold C, **Sala E**. The new FIGO Staging System for endometrial cancer: the implications for magnetic resonance imaging. *Radiographics* 2012; 32:241-254.
23. Lawrence EM, Priest AN, Gnanapragasam VJ, **Sala E**. The emerging role of Diffusion Weighted MRI in Prostate Cancer Management. *Nat Rev Urol* 2012; 9(2):94-101.

24. Moyle PM, **Sala E**. Magnetic resonance imaging of the cervix, and its relevance to the revised International Federation of Gynecology and Obstetrics (FIGO) staging. *Current Medical Imaging Reviews* 2012 May; 8(2):100-106.
25. deSouza NM, Kyriazi S, **Sala E**. Diffusion-weighted magnetic resonance imaging in pelvic cancer. *Current Medical Imaging Reviews* 2012 May; 8(2):92-99.
26. Khashper A, Addley HC, Abourokbah N, Nougaret S, **Sala E**, Reinhold C. T2-hypointense adnexal lesions: An imaging algorithm. *Radiographics* 2012; 32:1047-1064.
27. Freeman SJ, Aly AM, Kataoka MY, Addley HC, Reinhold C. **Sala E**. The revised FIGO staging of uterine malignancies: the implications for MR imaging. *Radiographics* 2012; 32(6):1805-27.
28. Nougaret S, Addley HC, Colombo PE, Fujii S, Al Sharif SS, Tirumani SH, Jardon C, **Sala E**, Reinhold C. Ovarian carcinomatosis: how can the radiologist help plan the surgical approach? *Radiographics* 2012; 32(6):1775-800.
29. Nougaret S, Tirumani S, Addley H, Pandey H, **Sala E**, Reinhold C. Pearls and Pitfalls in MRI of Gynecologic Malignancy using DWI. *AJR Am J Roentgenol* 2013; 200:261-278.
30. Vargas AH, Barrett T, **Sala E**. Magnetic Resonance Imaging of Ovarian Masses. *JMRI* 2013; 37:265–281.
31. **Sala E**, Rockall A, Freeman SJ, Mitchel D, Reinhold C. The added role of MRI in treatment stratification of patients with gynecological malignancies: What the radiologist needs to know. *Radiology* 2013; 266:717-740.
32. Miccò M, **Sala E**, Lakhman Y, Hricak H, Vargas HA. The role of imaging in the pre-treatment evaluation of ommon gynecological cancers. *Women’s Health*. 2014;10(3):299-321.
33. **Sala E**. *Obstetrics and Gynaecology Guidelines. Making the Best Use of a Department of Clinical Radiology*. The Royal College of Radiologists, UK 2014.
34. Vargas AH, Grimm I, Donati OF, **Sala E**, Hricak H. Molecular imaging of prostate cancer: translating molecular biology approaches into the clinical realm. *European Radiology* 2015; 25:1294-1302.
35. Lakhman Y, Stephanie N, Miccò M, Scelzo C, Vargas HA, Sosa R, Sutton EJ, Chi DS, Hricak H, **Sala E**. Role of MRI and FDG-PET/CT in the selection and follow-up of patients treated with pelvic exenteration for gynecologic malignancies. *Radiographics* 2015; 35:1294-1312.
36. Miccò M, **Sala E**, Lakhman Y, Hricak H, Vargas HA. Imaging features of uncommon gynecological cancers. *Am J Roentgenol* 2015; 205: 1346-1359.
37. Vargas HA, Lawrence EML, Mazaheri Y, **Sala E**. Updates in advanced diffusion-weighted magnetic resonance imaging techniques in the of prostate cancer. *World J Radiol* 2015 DOI: 10.4329/wjr.v7.i8.000.

38. Cowan RA, O'Cearbhaill RE, Chi DS, Gardner GJ, Levine DA, Long Roche K, Sonoda Y, Zivanovic O, Tew WP, **Sala E**, Lakhman Y, Vargas AH, Sarasohn DM, Mironov S, Abu-Rustum NR. Is it time to centralize ovarian cancer care in the United States? *Ann Surg Oncol* 2015 DOI 10.1245/s10434-015-4938-9
39. Benz RM, Vargas HA, **Sala E**. Functional MRI techniques in oncology in the era of personalized medicine. *MRI Clinics North America* 2016; 24:1-10.
40. Wibmer AG, Burger IA, **Sala E**, Hricak H, Weber WA, Vargas HA. Molecular imaging of prostate cancer. *Radiographics* 2016;36:142-161.

Books:

1. Freeman AH and **Sala E** (eds). *Radiology of Stomach and Duodenum*. Springer-Verlag, Berlin-Heidelberg-New York, 2007.
2. Hricak H, Akin O, **Sala E**, Reinhold C, Ascher S, Levine D (eds). *Diagnostic Imaging: Gynaecology*. Amirsys Inc, Salt Lake City, Utah, 2007.
3. **Sala E**, Freeman AH, Lomas DJ, Ringl H (eds). *Radiology for Surgeons in Clinical Practice*. Springer-Verlag, Berlin-Heidelberg-New York, 2008.
4. **Sala E**. Uterus (section ed.) in Hamm B and Ros PR (eds). *Abdominal Imaging*. Springer-Verlag, Berlin-Heidelberg-New York, 2013.

Book chapters:

1. **Sala E**, Allison S, Ascher SM, Hricak H. Imaging in Gynaecology. In: Adam A, Dixon AK (eds). *Grainger and Allison's Diagnostic Radiology. A textbook of Medical Imaging, Fifth edition*, Edinburgh, 2007; pp 1217-1241.
2. **Sala E**, Freeman AH. The acute Stomach and Duodenum. In Freeman AH and **Sala E** (eds) *Radiology of Stomach and Duodenum*, Springer-Verlag Berlin-Heidelberg-New York, 2007;pp 217-230.
3. **Sala E**, Freeman AH. Conventional Radiology of the Stomach and Duodenum. In Freeman AH and **Sala E** (eds) *Radiology of Stomach and Duodenum*, Springer-Verlag Berlin-Heidelberg-New York, 2007;pp 89-110.
4. Reeders J, Freeman AH, **Sala E**. Radiology-Pathology Correlation. In Freeman AH and **Sala E** (eds) *Radiology of Stomach and Duodenum*, Springer-Verlag Berlin-Heidelberg-New York, 2007;pp 5-28.
5. **Sala E** and Hricak H. Female Pelvis. In: Reiser, Semmler and Hricak. *Magnetic Resonance Tomography*. Springer-Verlag Berlin-Heidelberg-New York, 2007; pp 964-998.
6. **Sala E**, Hricak H. Reproductive. In Eisenberg RL. and Margulis AR (eds) *The Right Imaging Study: A guide for Physicians*, Springer-Verlag Berlin-Heidelberg-New York, 2008; pp 516-563.

7. Griffin N, **Sala E**, Breeze A, Proctor R. Obstetrics, Gynaecology and Breast. In Graham R and Gallagher F. (eds) Oxford Handbook of Emergencies in Clinical Radiology, Oxford University Press, 2009; pp 305-336.
8. Noel P, **Sala E**, Reinhold C. Imaging of abnormal uterine bleeding. In Morcos S and Thomsen H. (eds) Imaging of the Genitourinary System; Wiley & Sons Ltd, 2009; pp 381-398.
9. Griffin N, **Sala E**. Imaging in gynaecological oncology. In Shafi MI, Earl H. and Tan LT (eds) Gynaecological Oncology. Cambridge University Press, 2010; pp 51-68.
10. **Sala E**, Reznek R. Female pelvis. In Gourtsoyiannis N (ed) Clinical MRI of the Abdomen: Why, How, When. Berlin-Heidelberg-New York, 2011; pp 535-558.
11. DeSouza NM, **Sala E**, Kyriazi S, Rockall A. Functional imaging: from tumor biology to the clinic. In Kehoe S, Edmondsdon RJ, Gore M and McNeish IA (eds) Gynaecological Cancers: Biology and Therapeutics. RCOG Press, 2011; pp 1183-202.
12. **Sala E**, Lakhman Y, Ma W, Pannu H, Li D, Pandit-Taskar N, Hricak H. Diagnostic Imaging. In: Barakat RR, Berchuck A, Markman M, Randall ME (eds): Principles and Practice of Gynecologic Oncology, 6th ed. Philadelphia: Wolters Kluwer/Lippincott Williams & Wilkins, 2013; pp 244-283.
13. Moyle P, **Sala E**. Malignant Neoplasms, Staging of Ovarian Cancer. In Hamm B and Ros PR (eds). Abdominal Imaging. Springer-Verlag 2013; pp 2029-2040.
14. Burger IA, Freeman SJ, **Sala E**. Uterus: Imaging Techniques and Normal Anatomy. In Hamm B and Ros PR (eds). Abdominal Imaging. Springer-Verlag 2013; pp 2053-2062.
15. Moyle P, **Sala E**. Congenital Uterine Anomalies. In Hamm B and Ros PR (eds). Abdominal Imaging. Springer-Verlag 2013; pp 2063-2076.
16. Barrett T, Vargas AH, **Sala E**. Uterus: Follow-up and Detection of Recurrent Disease. In Hamm B and Ros PR (eds). Abdominal Imaging. Springer-Verlag 2013; pp 2121-2130.
17. Vargas AH, Barrett T, **Sala E**. Malignant Conditions of the Vulva. In Hamm B and Ros PR (eds). Abdominal Imaging. Springer-Verlag 2013; pp 2175-2182.
18. **Sala E**, Vargas HA, Donati OF, Weber W, Hricak H. Role of Molecular Imaging in the Era of Personalized Medicine: A Review. In Luna A, Vilanova JC, Hygino Da Cruz JC, Rossi S (eds) Functional Oncological Imaging, Springer-Verlag Berlin-Heidelberg-New York, 2014; pp 43-58.
19. **Sala E**, Freeman S, Ascher SM, Hricak H. Imaging of Gynaecological Malignancies. In: Adam A, Dixon AK, Gillard JH, Schafer-Prokop C. Grainger and Allison Diagnostic Radiology. A textbook of Medical Imaging, Sixth edition, 2014; pp 957-971.
20. **Sala E**, Hricak H. Prostate Carcinoma – Cross sectional imaging techniques. In: Manyak M, Harisingani M, de la Rosette J, Wijkstra H (eds) Imaging in Urologic Oncology, Springer-Verlag Berlin-Heidelberg-New York, 2014 (in press).

21. Freeman S, **Sala E**. Imaging in Gynecology. In Bieber E, Sanfilippo J, Horowitz I and Shafi MI (eds) Clinical Gynecology, Cambridge University Press, Cambridge, UK, 2015; 187-202.
22. Barrett T, Gill AB, **Sala E**. Female Pelvis. In Bammer R (ed) MR and CT Perfusion Imaging: Clinical Applications and Theoretical Principles, Lippincott Williams & Wilkins 2015 (in press).

3. Abstracts (optional)

4. Presentations (optional).

5. Patents

Kolesnick RN, Haimovitz-Friedman A, **Sala E**, Fuks, Z: U.S. Patent pending (No. 62/077,645), "Acid sphingomyelinase as a biomarker for combination therapy of anti-angiogenic and chemotherapy". (filed 11/10/2014).

Date: 03/06/2016